• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory & Compliance
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Special Content
    • Special Reports
    • In-Depth Coverage
    • DeviceTalks
  • Podcasts
    • MassDevice Fast Five
    • DeviceTalks Weekly
    • OEM Talks
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Resources
    • About MassDevice
    • DeviceTalks
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices
Home » Johnson & Johnson tops estimates, boosts earnings guidance

Johnson & Johnson tops estimates, boosts earnings guidance

October 18, 2011 By MassDevice staff

Johnson & Johnson

Johnson & Johnson (NYSE:JNJ) kicked off quarterly earnings season by beating Wall Street estimates and raising the bottom end of its earnings guidance, sending JNJ shares up modestly despite declining third-quarter earnings.

The New Brunswick, N.J.-based health care conglomerate reported profits of $3.20 billion, or $1.15 per diluted share, on sales of $16.01 billion for the three months ended Sept. 30.

That’s a bottom-line slide of 6.3 percent compared with earnings of $3.42 billion, or $1.23 diluted EPS, on sales of $15.0 billion during the same period last year.

Sign up to get our free newsletters delivered straight to your inbox

Absent a 9-cent-per-share charge to cover Johnson & Johnson’s $2.3 billion buyout of Synthes (VTX:SYST), however, earnings were $3.4 billion, or $1.24 per share – ahead of analysts’ expectations of $1.21 per adjusted share.

The company’s medical device & diagnostics division posted sales of $6.3 billion, up 6.1 percent largely due to a 12.3 percent boost from international revenues of $3.50 billion. U.S. sales were down 0.7 percent to $2.80 billion.

“Primary contributors to operational growth included Ethicon’s surgical care products; Ethicon Endo-Surgery’s Advanced Sterilization Products and international sales of minimally invasive products; and Biosense Webster’s electrophysiology business,” the company said in a press release.

Shares of JNJ were up 0.1 percent to $63.87 as of about 12:30 today.

Here’s a look at how the MD&D division’s segments broke down for the quarter (in millions):

CARDIOVASCULAR CARE
US $198 $246 -19.5%
Intl $328 $350 -6.3%
WW $526.00 $596.00 -11.7%
DEPUY
US $737 $748 -1.5%
Intl $647 $561 15.3%
WW $1,384.00 $1,309.00 5.7%
DIABETES CARE
US $338 $338 0.0%
Intl $326 $275 18.5%
WW $664.00 $613.00 8.3%
ETHICON ENDO-SURGERY
US $472 $484 -2.5%
Intl $759 $653 16.2%
WW $1,231.00 $1,137.00 8.3%
ORTHO-CLINICAL DIAGNOSTICS
US $265 $263 0.8%
Intl $274 $235 16.6%
WW $539.00 $498.00 8.2%
VISION CARE
US $251 $241 4.1%
Intl $501 $454 10.4%
WW $752 $695 8.2%

Filed Under: MassDevice Earnings Roundup, News Well, Wall Street Beat Tagged With: Johnson and Johnson, Q3

More recent news

  • Neuralink files to raise $649M in new equity offering
  • BofA: Surgical robot remanufacturing not a major setback for Intuitive
  • InspireMD wins CE Mark approval for CGuard Prime
  • Philips reports first cases for VeriSight Pro 3D ICE catheter in Europe
  • Ceryx Medical raises $15M to support bioelectronic pacemaker

Primary Sidebar

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >

MEDTECH 100 Stock INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy